Sun.Apr 06, 2025

article thumbnail

Hyman, Phelps & McNamara Enters its 45th Year Continuing to Expand its Capabilities to Meet Client Needs

FDA Law Blog: Biosimilars

Hyman, Phelps & McNamara (HPM) marks its 45thAnniversary year by welcoming three accomplished professionals who reinforce the depth and breadth of the firms FDA and DEA practices. Naomi Lowy joins HPM as a Principal Drug Regulatory Expert after 18 years at the FDAs Center for Drug Evaluation and Research (CDER), most recently as the Deputy Director, Division of General Endocrinology.

Nurses 59
article thumbnail

Knee Replacement Recovery Time: What You Need To Know

Drugs.com

SUNDAY, April 6, 2025 -- Wondering what recovery is really like after knee replacement surgery? Dr. Ayesha Abdeen, chief of hip and knee replacement surgery at Boston Medical Center, breaks down exactly what to expect -- from managing pain in the.

167
167
article thumbnail

FDA’s Vape Ban Hits the Right Note: Supreme Court Says “Let It Be”

FDA Law Blog: Biosimilars

By Andrew J. Hull & David B. Clissold & Sophia R. Gaulkin & Esther Petrikovsky Last week, the Supreme Court issued a unanimous decision in FDA v. Wages & White Lion Investments, LLC , No. 23-1038 (Apr. 2, 2025) that affirms FDAs denial of authorization to market flavored vape products. This opinion, which overrules a Fifth Circuit decision that FDA had acted arbitrarily and capriciously in denying premarket tobacco product applications submitted by manufacturers of flavored e-li

FDA 59